Holding on to statins in Parkinson disease

Neurology

Volumn 81, Issue 5, 2013, Pages 406-407

  Tan, Eng King ^a   Tan, Louis C S ^b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CALCIUM ION; CHOLESTEROL; CYTOCHROME C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MULTIDRUG RESISTANCE PROTEIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CASE CONTROL STUDY; CHINESE; COHORT ANALYSIS; DRUG USE; EDITORIAL; GENETIC VARIABILITY; HEALTH CARE POLICY; HUMAN; INCIDENCE; LIPID ANALYSIS; MULTIPLE SCLEROSIS; NATIONAL HEALTH INSURANCE; OXIDATIVE STRESS; PARKINSON DISEASE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLICATION;

FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PARKINSON DISEASE; POPULATION SURVEILLANCE;

EID: 84881271633     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31829d87bb     Document Type: Editorial

References (10)

1. Lewington S,Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829-1839.
2. Willey JZ, Elkind MS. 3-Hydroxy-3-methylglutarylcoenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol 2010;67:1062-1067.
3. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Arch Neurol 2012;69:380-384.
4. Undela K, Gudala K, Malla S, Bansal D. Statin use and risk of Parkinson̈s disease: a meta-analysis of observational studies. J Neurol 2013;260:158-165.
5. Lee YC, Lin CH, Wu RM, et al. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 2013;81:410-416.
6. Wood WG, Eckert GP, Igbavboa U, Müller WE. Statins and neuroprotection: a prescription to move the field forward. Ann NY Acad Sci 2010;1199:69-76.
7. Parihar A, Parihar MS, Zenebe WJ, Ghafourifar P. Statins lower calcium-induced oxidative stress in isolated mitochondria. Hum Exp Toxicol 2012;31:355-363.
8. Kumar A, Sharma N, Gupta A, Kalonia H, Mishra J. Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms. Brain Res 2012;1471:13-22.
9. Koob AO, Ubhi K, Paulsson JF, et al. Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol 2010;221:267-274.
10. Vladutiu GD, Isackson PJ. SLCO1B1 variants and statininduced myopathy. N Engl J Med 2009;360:304.